OLUX E (clobetasol propionate) by R-Pharm US is clinical pharmacology: the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. Approved for psoriasis, atopic dermatitis, seborrheic dermatitis and 2 more indications. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
OLUX E is a topical clobetasol propionate 0.05% foam formulation, a Class I (super-potent) corticosteroid approved in 2007 for inflammatory skin conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms characteristic of corticosteroids, with systemic absorption potential requiring monitoring of HPA axis suppression with prolonged use.
Product is in late-stage lifecycle with formulation patent expiring in 2.5 years; brand team focus shifts toward LOE planning and cost containment rather than growth.
CLINICAL PHARMACOLOGY: The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical…
Worked on OLUX E at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on OLUX E offers limited career growth due to approaching LOE (2.5 years remaining) and zero currently linked job openings; roles focus on defending market share against biosimilar and JAK inhibitor competition rather than driving growth. This is a stabilization/transition role suitable for experienced professionals managing the LOE lifecycle but not for those seeking expansion opportunities.